Business
UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
Conference Call and Webcast Scheduled for Monday, August 10, 2020 at 8:30 AM ET PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN), a
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\nConference Call and Webcast Scheduled for Monday, August 10, 2020 at 8:30 AM ET\n\n PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 2020 financial results on Monday, August 10, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.\n\n\nAudio Webcast\n\n\nThe webcast will be made available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for approximately two weeks.\n\n\nDial-In Information\n\n\nLive (U.S. / Canada): 1 (855) 765-5685\nLive (International): 1 (615) 247-5916\nConfirmation number: 9168696\n\n\nAbout UroGen Pharma Ltd.\nUroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s approved product, Jelmyto® (mitomycin) for pyelocalyceal solution, and pipeline treatment UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200803005156/en/\n\nINVESTOR CONTACT:\nPeter Pfreundschuh\nChief Financial Officer\[email protected]\n646-768-9531\n\n\nMEDIA CONTACT:\nEric Van Zanten\nSenior Director, Communications\[email protected]\n610-529-6219\n\nSource: UroGen Pharma Ltd.","le...